Rakovina Therapeutics Inc utilizes the Deep Docking AI Platform to accelerate drug discovery for oncology, focusing on biomarker-driven treatments for various tumor types. The company is developing a pipeline of potential therapies, including kt-2000 AI and the kt-3000 series, aimed at addressing the need for effective cancer treatments that target DNA damage response mechanisms.
Funding
$2.1M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
The discovery of new cancer treatments is a lengthy and expensive process, often taking many years and requiring significant resources. Traditional drug discovery methods can be inefficient in identifying promising drug candidates and predicting their effectiveness against specific tumor types. There is a need for more efficient and targeted approaches to accelerate the development of effective cancer therapies.
Solution
Rakovina Therapeutics is developing a pipeline of cancer therapies using its Deep Docking AI Platform to accelerate drug discovery. The platform focuses on biomarker-driven treatments for various tumor types, enabling the identification of drug candidates with a higher likelihood of success. By leveraging AI, Rakovina Therapeutics aims to address the need for effective cancer treatments that target DNA damage response mechanisms, potentially improving patient outcomes and saving lives worldwide. The company's research programs are committed to pushing the boundaries of discovery and research using the latest technological advances.
Target Audience
The primary target audience includes oncology researchers, pharmaceutical companies, and ultimately, cancer patients seeking more effective treatment options.
Features
- Deep Docking AI Platform for efficient drug candidate identification
- Focus on biomarker-driven treatments for targeted therapy
- Pipeline of potential therapies, including kt-2000 AI and the kt-3000 series
- Targeting DNA damage response mechanisms in cancer cells